Semaglutide (Wegovy, Novo Nordisk) is indicated 'as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (body mass index [BMI] ≥27 kg/m2)'.
The dosage schedule is available in the summary of product characteristics for semaglutide.
For this evaluation, semaglutide was considered at a maximum maintenance dose of 2.4 mg once weekly.
The list price of semaglutide 2.4 mg is £175.80 per pack, of 1.7 mg is £124.53 per pack, and of 0.25 mg, 0.5 mg and 1.0 mg is £73.25 per pack (excluding VAT; BNF online accessed March 2026). Each pack contains 1 pen that delivers 4 doses.
The company has a commercial arrangement. This makes semaglutide available to the NHS with a discount. The details of this arrangement are commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published in Novo Nordisk's NHS carbon reduction plan.